FLT3 and acute myeloid leukemia: The FLT3-ITD allelic ratio no longer influences risk classification; instead, AML with FLT3-ITD (without adverse-risk genetics) is now categorized as intermediate-risk due to assay standardization challenges and the increasing significance of MRD [27].